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Abstract
The aim of this study was to evaluate the impact of carbapenem-resistant K. pneumoniae bloodstream infections on mortality. During
the study period 42, 68 and 120 patients were identiﬁed with carbapenem-resistant, extended-spectrum b-lactamase producers (ESBL)
and susceptible K. pneumoniae bloodstream infections, respectively. Patients with carbapenem-resistant K. pneumoniae had higher rates
of prior antimicrobial exposure, other nosocomial infections, and use of invasive devices. Infection-related mortality was 48% for carba-
penem-resistant, 22% for ESBL producers and 17% for susceptible K. pneumoniae. Independent risk factors for infection-related mortality
were Pitt bacteraemia score, Charlson score and carbapenem resistance.
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Introduction
Klebsiella pneumoniae is one of the most common hospital-
acquired Gram-negative pathogens [1]. During the last dec-
ade, the spread of extended-spectrum b-lactamase (ESBL)-
producing enterobacteriacae has resulted in limited treat-
ment options and increased use of carbapenem antibiotics
[2]. Carbapenem-resistant K. pneumoniae (CRKP) was ﬁrst
reported in 1996, and is now found worldwide [3–5]. In
recent years, CRKP strains have been described in several
outbreaks of nosocomial infections and are increasingly pre-
valent in parts of the US and Israel [6,7].
While previous studies have focused on the epidemiology,
laboratory detection methods and molecular characterization
of carbapenemase-producing bacteria [8,9], only a few stud-
ies have assessed the signiﬁcance of carbepenem resistance
on clinical outcomes [10–12].
During 2006 we have noticed a marked increase in the
number of CRKP isolates in our medical centre. We have
conducted the current study to describe the epidemiology of
K. pneumoniae bloodstream infection (BSI) and to determine
whether carbapenem resistance has an impact on mortality.
Methods
Setting and participants
This study was approved by the Institutional Review Board
of Sheba Medical Center, a 1600-bed tertiary care university
teaching hospital in central Israel.
We conducted a retrospective cohort study of hospitalized
patients with K. pneumoniae BSI between January and Decem-
ber 2006. The patients were identiﬁed through records of the
clinical microbiology laboratory. Only the ﬁrst episode of multi-
ple K. pneumoniae isolations was included, and patients with
polymicrobial BSI were excluded. Patients’ data were obtained
from the medical records, and included demographic character-
istics, comorbid conditions and Charlson Comorbidity Index
[13]. Events during hospitalization included duration of hospital
stay prior to infection, previous intensive care unit (ICU) stay,
use of invasive devices, mechanical ventilation, presence of
other nosocomial infections, and antimicrobial therapy adminis-
trated during the 30 days prior to the onset of BSI.
To estimate the impact of colonization pressure, the num-
ber of CRKP acquisitions during the 30 days preceding the
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infection was documented for all hospital wards. Nosocomial
infections were determined according to the CDC deﬁni-
tions [14]. Severity of illness during the onset of BSI was cal-
culated by the means of the Pitt bacteraemia score [15].
Antimicrobial therapies were classiﬁed as empiric or deﬁnite
depending on whether they were administered before the
results of blood culture became known or after the antibi-
otic susceptibilities were determined. Antimicrobial therapy
was considered appropriate if the treatment regimen
included antibiotics that were active in vitro.
Outcome
The effect of carbapenem resistance on clinical outcomes was
evaluated by the assessment of in-hospital mortality and infec-
tion-related mortality. Mortality attributable to BSI was
deﬁned by clinical evidence of active infection and positive cul-
tures, or when death occurred as the result of organ failure
that developed or deteriorated during the onset of infection.
Microbiological methods
Clinical isolates were identiﬁed by standard laboratory meth-
ods using an automated Bactec 9240 system (Becton, Dickin-
son and Company, Sparks, MD, USA). Susceptibility testing
was performed according to the Clinical and Laboratory
Standards Institute guidelines [16]. For identifying ESBL pro-
duction, disks were routinely placed with the cephalosporins
on either side of the amoxicillin/clavulanic acid for screening
by the disk approximation method. Isolates were conﬁrmed
as ESBL producers using the double-disk synergy test [17].
Carbapenem resistance was conﬁrmed by the Kirby–Bauer
disk-diffusion method on Mueller Hinton plates (BD Diagnos-
tics, Heidelberg, Germany) using ertapenem (10 lg), me-
ropenem (10 lg) and imipenem (10 lg) (Oxoid, Basingstoke
UK), and by Etest (AB Biodisk, Solna, Sweden).
Isolates were screened for blaKPC by PCR as described
recently [18]. We have developed and validated a real-time
PCR assay for detecting blaKPC genes. Brieﬂy, bacterial DNA
was extracted from vortexed perianal swabs. TaqMan tech-
nology was used for detecting blaKPC, using primer sequences
that were designed in-house. Sensitivity and speciﬁcity of the
real-time PCR were 100% and 95%, respectively. The genetic
relatedness of both CRKP and ESBL strains was determined
by pulsed-ﬁeld gel electrophoresis (PFGE) analysis. DNA was
prepared as described previously [18], and chromosomal
restriction fragments obtained after XbaI and SpeI cleavage
were documented and compared.
Statistical analysis
The data were analysed with the SPSS version 12.0. Nor-
mally distributed continuous variables were compared with
the Student t-test, and non-normally distributed continuous
variables by the Wilcoxon rank sum test. The chi-square test
or the Fisher exact test was used to compare categorical
variables. Multivariable regression models were constructed
stepwise. For model building, parameters with p values £0.1
between groups in the univariate analysis were entered into
the model. In the multivariate analysis, variables with p £0.05
were considered signiﬁcant. Kaplan–Meier survival curves
were used for survival analysis. All p values were two-tailed,
with a p value of <0.05 considered statistically signiﬁcant.
We declare no conﬂicting or dual interests.
Results
During 2006, 210 patients hospitalized at Sheba Medical Cen-
ter had K. pneumoniae BSI. Eighteen patients had polymicrobi-
al bacteraemia, and therefore 192 patients were included in
the study.
Forty-two patients (22%) developed BSI with CRKP, 65
(34%) with extended-spectrum b-lactamase-producing
K. pneumoniae (ESBLKP) and 85 (44%) with susceptible
K. pneumoniae (SKP). Patients’ characteristics are shown in
Table 1. Among the three groups, there were no signiﬁcant
differences in the demographic parameters, number of hospi-
talizations within the prior 12 months, or the Charlson
co-morbidity score. A signiﬁcant difference was observed in
several hospital events prior to the onset of infection, includ-
ing length of stay, nosocomial acquisition, ICU stay, use of
invasive devices, and exposure to antimicrobial therapy.
Patients with CRKP BSI were more likely to be hospitalized
in a ward where other cases of CRKP were identiﬁed during
the preceding 30 days. A signiﬁcant difference was a noted in
the Pitt bacteraemia score. Patients with SKP BSI had a low
Pitt bacteraemia score of 2, compared with patients with ES-
BLKP or CRKP (scoring 3 and 4, respectively; p <0.001). Sig-
niﬁcant differences were also documented in the proportions
of appropriate empirical antimicrobial therapy (79%, 39% and
12%, respectively; p <0.001).
Outcome measures of patients with K. pneumoniae BSI are
shown in Table 2. Infection-related mortality was signiﬁcantly
higher among patients with CRKP, compared with those with
ESBLKP or SKP BSI (48%, 22% and 17%, respectively). Uni-
variate analysis of predictors for infection-related mortality is
shown in Table 3. After multivariate analysis, Charlson co-
morbidity score, Pitt bacteraemia score and carbapenem
resistance remained independent predictors (Table 4). ESBL
production was not associated with increased crude mortal-
ity or infection-related mortality. Cox regression analysis
revealed carbapenem resistance to be a signiﬁcant factor for
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mortality (log-rank test: p 0.006). The survival curve for
K. pneumoniae BSI is shown in Fig. 1.
PFGE analysis of 14 random CRKP isolates demonstrated
the same clone (Fig. 2a). PCR revealed the presence of
blaKPC-3 in all isolates (Fig. 2b). In contrast, PFGE analysis of
eight random isolates of KP ESBL demonstrated eight distinct
clones. blaKPC-3 was not found among all KP ESBL producer
isolates.
Discussion
This study was undertaken to evaluate the epidemiology
and risk factors for mortality of patients with K. pneumo-
niae BSI. We found that severity of illnesses and carbape-
nem resistance were strong prognostic factors for
mortality.
TABLE 1. Demographic and clinical characteristics of patients with K. pneumoniae bloodstream infections




Male (%) 48 (57) 35 (54) 28 (67) 0.4
Age, years, median (IQR) 71 (28) 73 (22) 73 (27) 0.97
Previous hospitalizations during
prior 12 months (%)
40 (47) 39 (60) 23 (55) 0.28
Charlson score, median (IQR) 3 (4) 3 (4) 3 (3) 0.47
Co-morbidities (%)
Myocardial infarction 13 (17) 6 (11) 8 (19) 0.45
Chronic heart failure 18 (23) 4 (7) 11 (26) 0.02
Stroke 16 (20) 19 (33) 7 (17) 0.11
Dementia 7 (9) 7 (12) 5 (12) 0.79
Chronic lung disease 7 (9) 11 (19) 6 (14) 0.23
Peptic ulcer 1 (1) 5 (9) 11 (26) 0.001
Diabetes mellitus 27 (34) 19 (33) 15 (36) 0.95
Chronic renal failure 16 (21) 13 (23) 16 (39) 0.07




LOS before BSI, median days (IQR) 8 (16) 16 (22) 12 (26) 0.019
Nosocomial acquisition (%) 67 (79) 62 (95) 42 (100) 0.001
ICU stay (%) 18 (21) 21 (32) 24 (57) <0.001
Urinary catheter (%) 34 (40) 41 (63) 31 (74) <0.001
Central venous catheter (%) 22 (26) 19 (29) 21 (50) 0.019
Surgical procedure (%) 24 (28) 24 (37) 17 (41) 0.32
Dialysis (%) 2 (2) 5 (8) 7 (17) 0.014
Other patients with CRKP on the ward (%) 37 (44) 23 (35) 31 (74) <0.001
Nosocomial pneumonia (%) 11 (13) 18 (28) 16 (38) 0.004
Surgical site infection (%) 2(2) 5 (8) 5 (12) 0.09
Prior antimicrobial treatment (%) 27 (32) 45 (70) 38 (91) <0.001
Fluoroquinolones 6 (7) 21 (32) 19 (45) <0.001
Carbapenem 5 (6) 12 (18) 11 (26) 0.006
Cephalosporin 8 (9) 13 (20) 21 (50) <0.001
Pipril tazobactam 27 (32) 45 (70) 38 (91) <0.001
Events on the
onset of BSI
Pitt bacteraemia score, median (IQR) 2 (4) 3 (5) 4 (5) 0.002
Appropriate antibiotic empirical therapy (%) 67 (79) 25 (39) 5 (12) <0.001
BSI, bloodstream infection; CRKP, carbapenem-resistant K. pneumoniae; ESBLKP, extended-spectrum beta lactamase-producing K. pneumoniae; IQR, interquartile range; LOS,
length of stay; SKP, susceptible K. pneumoniae.








(n = 42) p
In-hospital mortality (%) 20 (24) 25 (39) 29 (69) <0.001
Infection-related mortality (%) 14 (17) 14 (22) 20 (48) 0.001
LOS after infection, median
days (IQR)
9 (16) 16 (34) 18 (22) 0.003
Total LOS, median days (IQR) 21 (36) 36 (70) 37 (31) 0.001
CRKP, carbapenem-resistant K. pneumoniae; ESBLKP, extended-spectrum beta
lactamase-producing K. pneumoniae; IQR, interquartile range; LOS, length of stay;
SKP, susceptible K. pneumoniae.







Male (%) 71 (60) 40 (54) 0.4
Age, years, median ± SD 67 ± 19 70 ± 17 0.34
Chemotherapy (%) 22 (19) 7 (10) 0.08
Charlson co-morbidity score,
median (SD)
3.4 (2.9) 4.3 (3.4) 0.04
Myocardial infarction (%) 11 (11) 16 (22) 0.04
Chronic heart failure (%) 17 (16) 16 (22) 0.3
Stroke (%) 26 (25) 16 (22) 0.6
Dementia (%) 13 (13) 6 (8) 0.3
Chronic lung disease (%) 11 (11) 13 (18) 0.16
Diabetes (%) 37 (35) 24 (33) 0.8
Diabetes with end-stage
organ failure (%)
6 (6) 10 (14) 0.07
Malignancy (%) 39 (34) 25 (34) 0.98
Renal failure (%) 24 (23) 21 (29) 0.36
Previous hospitalization (%) 57 (48) 45 (61) 0.09
LOS before infection, mean
days ± SD
25 ± 81 27 ± 37 0.87
Intensive care unit stay (%) 26 (22) 37 (50) <0.001
Mechanical ventilation 25 (21) 44 (60) <0.001
Urinary catheter (%) 49 (42) 57 (77) <0.001
Surgical procedure (%) 35 (30) 30 (41) 0.12
Central venous catheter (%) 37 (31) 25 (34) 0.73
Dialysis (%) 3 (3) 11 (15) 0.001
Prior antimicrobial therapy (%) 59 (50) 51 (69) 0.01
Other nosocomial infection (%) 41 (35) 51 (69) <0.001
Pitt bacteraemia score, average ± SD 1.7 ± 2.0 6.3 ± 1.7 <0.001
LOS, length of stay.
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The impact of antibiotic resistance on the outcome for
patients with nosocomial infections is controversial. Although
it is generally accepted that drug resistance is associated with
increased morbidity and mortality [17,19], some studies
found no such relationship [20,21]. Underlying co-morbidi-
ties, delay in the initiation of appropriate antimicrobial ther-
apy, and the severity of illness of the patients infected by the
multidrug-resistant pathogens, may be important confound-
ers [22,23]. Therefore, appropriate adjustment for these
confounding factors is essential in studies that determine the
impact of antimicrobial resistance. In the present study, we
found that carbepenem resistance was an independent risk
factor for mortality among patients with K. pneumoniae BSI.
Recently, a few studies have demonstrated that carbapenem
resistance was associated with increased mortality. Patel
et al. [12] have included in their study various infections,
while Schwaber et al. [10] have included patients with clinical
isolates that may represent only colonization. In both studies,
control patients had a signiﬁcantly shorter length of hospital
stay compared with case patients (a median of 2 days com-
pared with more than 20 days). Therefore, these control
infections may represent community-acquired infections that
may have different outcomes relative to nosocomial infec-
tions [15].
Our study is one of the ﬁrst to assess the impact of carb-
apenem resistance on the outcome of K. pneumoniae BSI. In
contrast to previous studies, we have divided the cohort into
three levels of bacterial resistance: susceptible, ESBL and
carbapenemase-producing strains. Patients with BSI from the
latter two strain types had a longer hospital stay, were
admitted to intensive care, acquired the infection in hospital,
and had been exposed to invasive procedures and to prior
antimicrobial therapy. Nevertheless, only carbapenem resis-
tance was associated with increased mortality. Although
some studies have suggested that increased mortality was
associated with ESBL producer strains [17,24], this ﬁnding
was contended by others [20,25]. A recent systematic
review showed that although infections caused by ESBL pro-
ducers were associated with increased mortality, only one of
16 studies was controlled for confounding factors [26].
The clonality of K. pneumoniae isolates was analysed by
comparing PFGE proﬁles. The eight ESBL producers were all
different; in contrast, all CRKP isolates were found to be
TABLE 4. Independent risk factors for mortality among
patients with Klebsiella pneumoniae bloodstream infections
Variable Adjusted OR (95% CI) p
All cause mortality
Charlson co-morbidity score 1.3 (1.09–1.47) 0.01
Pitt bacteraemia score 1.86 (1.54–2.25) <0.001
Carbapenem resistance 8.17 (2.66–25.12) <0.001
ESBL production 1.69 (0.63–4.5) 0.23
Infection-related mortality
Charlson co-morbidity score 1.18 (1.97–22.67) 0.02
Pitt bacteraemia score 1.54 ((1.34–1.77) <0.001
Carbapenem resistance 3.89 (1.34–11.25) 0.01
ESBL production 1.20 (0.43–3.36) 0.72
CI, conﬁdence interval; ESBL, extended-spectrum b-lactamase; OR, odds ratio.
FIG. 1. Survival curve for patients with K. pneumoniae bloodstream infections adjusted for Pitt bacteraemia score and Charlson co-morbidity
score.
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identical. Therefore, we cannot determine whether the high
mortality rates associated with carbapenem resistance are
due to antimicrobial resistance and inappropriate therapy, or
alternatively, to a highly virulent clone. All CRKP isolates
harboured blaKPC. Recent molecular studies have found that
closely related K. pneumoniae strains carrying blaKPC have
spread in several healthcare facilities in the United States and
Israel [27,28]. The occurrence of a dominant clone in two
continents demonstrates the potential of a single extensively
drug-resistant strain to spread globally. It was suggested that
the acquisition of a blaKPC gene may confer on this isolate of
K. pneumoniae a marked selective advantage that is leading to
its successful dissemination [29].
We used Pitt bacteraemia score to assess the severity of
illness [15]. This score was shown to predict mortality bet-
ter than APACHE score among patients with BSI [30,31].
Variables included in the score have occurred on the day
of the ﬁrst positive culture, and therefore we consider this
score to represent the true baseline. The effect of different
time points of severity score measurement on patients’
outcome has been recently assessed, and it was suggested
that severity of illness should be measured close to the
onset of infection [32]. Of note, Pitt bacteraemia score and
appropriate antimicrobial therapy represent variables that
occurred at the time of the ﬁrst positive blood culture, and
therefore may be intermediate variables and not confound-
ers. Adjustment for intermediate variables could underesti-
mate the magnitude of the relationship between exposure
and outcome. However, our results did not change when
the logistic regression for mortality was performed with
or without the Pitt bacteraemia score or appropriate
antimicrobial therapy.
The observed increased mortality among patients with
CRKP BSI may be the result of ineffective antimicrobial
therapy. There was a signiﬁcant difference in the propor-
tion of patients who received appropriate empirical ther-
apy among patients with susceptible KP, KP ESBL
producers and CRKP infections: 79%, 39% and 12%,
respectively. However, gentamicin, colistin and tigercycline
have been considered last-resort treatment against these
extremely drug-resistant microorganisms. Although few
reports have described favourable outcomes [33,34], no
controlled studies have assessed the efﬁcacy of these drugs
in serious nosocomial infections. In a recent report, appro-
priate empirical treatment was not associated with
improved survival among patients with CRKP infections
[12].
Our study has several limitations. Firstly, clinical data were
obtained retrospectively from medical records. There may
be differences in physician practices or accuracy of informa-
tion. Our retrospective design makes our results susceptible
to the limitations and potential biases of studies of similar
design. Secondly, patients with various admission diagnoses
were included in the cohort. As the number of patients in
each admission diagnosis category was small, we could
not assess the impact of different admission diagnoses on
(a)
(b)
FIG. 2. Pulsed-ﬁeld gel electrophoresis of 24 isolates of Klebsiella
pneumoniae. (a) Fourteen isolates of carbapenem-resistant Klebsiella
pneumonia; (b) eight isolates of ESBL-producing Klebsiella pneumoniae.
Arrows represent the controls.
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outcome. In addition, follow-up was limited to the hospital-
ization period. Therefore, we were able to analyse only in-
hospital mortality.
In conclusion, we found that carbapenem resistance in
K. pneumoniae was associated with increased mortality. Our
ﬁndings reinforce the urgent efforts needed to prevent the
spread of carbapenemases producing Enterobacteriaceae.
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